Jorge Cortes, MD, and Stephen A. Strickland Jr, MD, MSCI,discuss how in the management of chronic myeloid leukemia (CML), clinicians must carefully monitor early treatment response milestones with first-line tyrosine kinase inhibitor therapy, consider appropriate switching strategies including BCR::ABL1 mutation testing, and select between newer agents such as asciminib and ponatinib based on patient-specific factors, trial data, and distinct safety profiles, particularly regarding cardiovascular toxicities.
Panelists discuss how in standard clinical practice, response to first-line tyrosine kinase inhibitor therapy is monitored through regular molecular testing of BCR::ABL1 transcript levels, with key evaluations to assess whether patients achieve target milestone responses that predict long-term outcomes.
Panelists discuss how mutation analysis should be considered when treatment fails to meet milestones or patients show loss of response to tyrosine kinase inhibitor (TKI) therapy, as this information helps determine whether to continue the current TKI or switch to an alternative agent based on the specific resistance profile.
Panelists discuss how for patients with chronic myeloid leukemia who develop the T315I mutation, ponatinib and asciminib have demonstrated efficacy in the PACE and ASCEMBL trials, respectively, with ponatinib showing a major cytogenetic response rate in patients with T315I mutation and asciminib demonstrating superior major molecular response vs bosutinib.
Panelists discuss how when choosing between asciminib and ponatinib for chronic myeloid leukemia treatment, key considerations include the patient’s mutation status, prior tyrosine kinase inhibitor therapy response, cardiovascular risk factors and comorbidities, and the differing safety profiles of the 2 drugs, with ponatinib generally having more cardiovascular concerns but broader mutation coverage vs asciminib’s more favorable tolerability but more specific targeting of BCR::ABL1.
Panelists discuss how clinicians should implement regular cardiovascular monitoring and dose modifications for ponatinib-associated toxicities while being vigilant for asciminib’s key adverse events, including thrombocytopenia, pancreatic dysfunction, and hypertension, with appropriate dose adjustments and supportive care as needed.
Panelists discuss how in selecting first-line therapy for patients with newly diagnosed chronic myeloid leukemia, clinicians must carefully weigh factors including the patient’s risk score, comorbidities, drug interaction potential, monitoring requirements, and cost considerations while recognizing that available tyrosine kinase inhibitor options (imatinib, nilotinib, dasatinib, and bosutinib) have similar efficacy but distinct safety and tolerability profiles.
Panelists discuss how a clinician seeks guidance on implementing asciminib in first-line chronic myeloid leukemia treatment following its FDA approval, including understanding its trial data and determining appropriate patient selection compared with existing tyrosine kinase inhibitor options.
Panelists discuss how it is an exciting time for chronic myeloid leukemia (CML) treatment, with many options including 6 different drugs that have been very successful for patients, which give clinicians multiple options to tailor the therapy to their patients and consider whether CML could be curable.
